-
The Dr. Dean Ornish Program for Reversing Heart Disease is a dramatic lifestyle change for most people who have coronary artery disease or are at risk for the condition.
-
At Highmark Blue Cross Blue Shield, case managers are a vital component of the companys Dr. Dean Ornish Program for Reversing Heart Disease.
-
-
CardioGenesis (Foothill Ranch, California) reported that Chairman and Chief Executive Officer Michael Quinn has resumed the position of president, replacing Darrell Eckstein, who left the company to pursue other interests.
-
Abbott Laboratories (Abbott Park, Illinois) unveiled a collaboration and license agreement with global pharmaceutical company Wyeth (Madison, New Jersey) to develop an automated blood test to monitor therapeutic levels of the anti-rejection drug Rapamune.
-
One of the real buzzes at Novembers annual scientific sessions of the American Heart Association (AHA; Dallas, Texas) was the continuing clinical validation of the role of public access defibrillation in reducing mortality. Clinical studies showing the effectiveness of automated external defibrillators (AEDs) presented at the AHA conference were excellent news for virtually every major defibrillator company.
-
-
-
TFD as a single measurement carries significant prognostic importance in women with comprehensively staged endometrial cancer.
-
Most Americans believe that screening tests for cancer save lives and that it is irresponsible not to undergo recommended periodic screening. The presence of a large market for cancer screening may make Americans vulnerable to unproven and unnecessary testing.
